New study aims to personalize throat cancer treatment using genetic tests and MRI
NCT ID NCT07407205
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study looks at whether genetic markers (like tumor mutations and DNA in the blood) and special MRI scans can predict how well chemoradiotherapy works for patients with HPV-negative oropharyngeal cancer. Researchers will follow 30 patients to see if these tests can forecast treatment response and disease progression. The goal is to tailor therapy and reduce the number of follow-up scans needed.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- What this could lead to
- If successful, this could help doctors predict which patients will respond best to chemoradiotherapy, potentially personalizing treatment and reducing unnecessary scans.
- What could go wrong
- This is a small, early-stage study with only 30 participants, so results may not apply to everyone. The biomarkers being tested may not reliably predict outcomes.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 30 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Jun 2019
- Expected to finish
-
Dec 2026
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Age ≥ 18 years * Histologically confirmed HPV-negative oropharyngeal squamous cell carcinoma * Planned treatment with concurrent chemoradiotherapy * Ability to undergo MRI examination * Signed informed consent Exclusion Criteria: * HPV-positive oropharyngeal carcinoma * Contraindications for MRI * Severe comorbidities preventing chemoradiotherapy * Pregnancy or breastfeeding * Inability to comply with study procedures
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HPV-negative oropharyngeal cancer are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Institute of Oncology Ljubljana
Ljubljana, 1000, Slovenia
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can steroid shots shield salivary glands from radiation damage?
- Can tumor genetics unlock gentler treatments for head and neck cancer?
- Can less radiation be safer for throat cancer?
- Can a simple swab predict who needs less radiation?
- New drug combo aims to shrink oral cancers before surgery
- Acupuncture timing may be key to preventing dry mouth in head and neck cancer patients